What is Hesperos?
Hesperos, Inc. is a pioneering entity in the characterization of individual human biology through its sophisticated Human-on-a-Chip microfluidic systems. Building on the foundational work of its founders, Michael L. Shuler and James J. Hickman, who have been instrumental in the field's major scientific advancements, Hesperos has developed interconnected multi-organ systems. These pumpless platforms, utilizing serum-free cellular mediums, facilitate inter-organ communication and integrated computational PKPD modeling. The company's mission is to transform toxicology testing and drug discovery efficacy evaluation by providing functional readouts from a comprehensive array of human tissues and physiological systems.
How much funding has Hesperos raised?
Hesperos has raised a total of $235K across 2 funding rounds:
Debt
$150K
Debt
$85K
Debt (2020): $150K with participation from PPP
Debt (2021): $85K led by PPP
Key Investors in Hesperos
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Hesperos?
With its large-scale late-stage funding, Hesperos is strategically positioned for significant scaling and market penetration. The substantial expansion capital will likely fuel advancements in its Human-on-a-Chip technology, enabling broader adoption in drug discovery and toxicology. Future developments may include enhanced computational modeling capabilities and the expansion of its platform to encompass a wider range of physiological responses, solidifying its leadership in predictive human biology.
See full Hesperos company page
